Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

34.03 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
Via Benzinga
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028
Ultragenyx sees rising revenue and analyst support as key drug launch approaches, with potential profitability projected for 2027. 
Via Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Earnings Scheduled For May 6, 2025
Via Benzinga
Ultragenyx Pharmaceutical's Earnings: A Preview
Via Benzinga
Breaking Down Ultragenyx Pharmaceutical: 7 Analysts Share Their Views
Via Benzinga
Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Earnings Scheduled For February 13, 2025
Via Benzinga
Breaking Down Ultragenyx Pharmaceutical: 11 Analysts Share Their Views
Via Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning
JP Morgan sees strong upside for Ultragenyx, citing setrusumab trial progress and pipeline growth, raising the price target to $117. 
Via Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 11 Analysts
Via Benzinga
Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews
Via Benzinga
Ultragenyx to Participate at Investor Conferences in March
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
FDA decision expected by August 18, 2025 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside
Ultragenyx forecasts 2024 revenue above estimates, highlights confidence in setrusumab trial progress, and outlines plans for regulatory filings in 2025. 
Via Benzinga
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. 
Via Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.